REG - Belluscura PLC - Result of General Meeting

BelluscuraAnnouncement

08/07/2024 12:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240708:nRSH5382Va&default-theme=true

RNS Number : 5382V  Belluscura PLC  08 July 2024

8 July 2024

 

Belluscura plc

("Belluscura", the "Company"}

 

Result of General Meeting

 

Belluscura plc (AIM: BELL), a leading medical device developer focused on
lightweight and portable oxygen enrichment technology, announces that at the
General Meeting held earlier today both the resolutions put to the meeting
were duly approved by Shareholders:

 

 Resolution                                       Votes for   % of shares voted  Votes against  % of shares voted

(*indicates special resolution)
 Resolution 1:  To allot Shares re. Loan Notes.   98,167,364  99.90%             101,411        0.10%
 Resolution 2*:  To disapply Statutory            98,167,364  99.90%             101,411        0.10%

Pre-Emption Rights re. Loan Notes.

 

The Company is pleased to confirm that, as announced on 2 July 2024, following
Shareholder approval for the Resolutions as they relate to the issue of the
Loan Note Placing, together with the recent Share Subscriptions for new
ordinary shares, the Company has raised total gross proceeds of approximately
£1.92 million.

 

In accordance with the terms of the Loan Note Placing Agreement, following
passing of the Resolutions, the Placing Loan Notes will be issued on 9 July
2024.

 

The net proceeds of the Loan Note Placing and Share Subscriptions will be used
for working capital purposes to support the growth in both the X-PLOR® and
DISCOV-R(TM) portable oxygen concentrator devices sales, as set out in the
Announcement and the Letter to Shareholders dated 2 July 2024.

 

 

Capitalised terms used in this announcement shall, unless defined in this
announcement or unless the context provides otherwise, bear the same meaning
ascribed to such terms in the Announcement made by the Company at 14:30 on 2
July 2024 and the letter to Shareholders dated 2 July 2024, which constituted
a supplement to the Circular dated 14 June 2024.

 

For further information please contact:

                                              Tel: +44 (0)20 3128 8100

 Belluscura plc
 Adam Reynolds, Chairman

 Robert Rauker, Chief Executive Officer

 Simon Neicheril, Chief Financial Officer

 SPARK Advisory Partners Limited (Nomad)      Tel: +44 (0)20 3368 3550
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited (Broker)             Tel: +44 (0)20 3903 7715
 Russell Cook / Nicholas Chambers

 MHP (Financial PR & Investor Relations)      Tel: +44 (0)20 3128 8100
 Katie Hunt / Matthew Taylor                   belluscura@mhpgroup.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMEAFXPELELEFA